Oligo Pools Market Size, Share & Industry Analysis, By Type (DNA Oligo Pools, RNA Oligo Pools, Specialty/Modified Pools, and Others), By Application (Next Generation Sequencing, CRISPR/Functional Genomics, Gene Variant Libraries, and Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CDMOs, and Others), and Regional Forecast, 2026-2034

The global oligo pools market size was valued at USD 0.70 billion in 2024 and is projected to reach USD 1.80 billion by 2032, exhibiting a CAGR of 12.5% during the forecast period. Oligo pools refer to multiple short DNA or RNA sequences synthesized simultaneously. These pools are essential for various applications such as gene synthesis, drug discovery, diagnostics, and research. The increasing demand for genomics, personalized medicine, and synthetic biology is expected to boost the adoption of these products and services in the market.

• For instance, in April 2025, Creyon Bio, Inc. collaborated with Lilly to focus on the discovery, development, and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases.

Oligo Pools Market Driver

Growing Demand for Oligos for Therapeutics and Diagnostics Purposes to Drive Market Growth

The rising demand for oligonucleotides in therapeutics and diagnostics is a key driver of the oligo pools market. The surging prevalence of chronic diseases and increasing demand for targeted therapies and personalized medicine, and for diagnostic assays require high-quality, customizable oligo pools. Additionally, key players in the market are focusing on offering new products for therapeutics and diagnostics purposes to accelerate the market growth.

• For instance, in May 2025, Oligo Factory announced the launch of a new low-scale oligo synthesis capability to support the development lifecycle of oligo-based therapeutics, including discovery, preclinical and toxicology studies as well as molecular diagnostic applications.

Download Free sample to learn more about this report.

According to the American Pharmaceutical Review, worldwide, the spending on precision medicine treatment was about USD 32 billion in 2022 and it is set to grow to USD 124 billion by 2027.

Oligo Pools Market Restraints

Lack of Clear Regulatory Infrastructure to Hamper Market Growth

The oligo pools market has seen an increased demand for products and services. However, the lack of a regulatory framework for the development and manufacturing of genes and oligonucleotides is expected to hamper the global market growth during the forecast period.

• In September 2022, the European Medicines Agency issued a concept paper proposing the development of a guideline specifically for the development and manufacturing of synthetic oligonucleotides. This guideline aims to address aspects such as manufacturing processes, characterization, specifications, and analytical controls that are not covered by existing guidelines on the chemistry of active substances for human and veterinary medicines.

Oligo Pools Market Opportunity

Demand for Rapid Synthesis Services to Offer Lucrative Growth Opportunity

The rising research and development activities and demand for adequate and faster supply of oligo pools for drug development, or personalized medicine development, are expected to propel the market during the forecast period. Additionally, key players in the market are focusing on offering faster services to reduce turnaround time to boost product adoption and demand.

• For instance, in November 2023, Twist Bioscience announced the launch of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.

Segmentation

Key Insights

The report covers the following key insights:

• New Product Launches
• Key Industry Developments (Merger, Acquisitions, Partnerships, and Others)
• Technological Advancements in Oligo Pools

Analysis by Type

Based on type, the market is subdivided into DNA oligo pools, RNA oligo pools, specialty/modified pools, and others.

The DNA oligo pools segment dominated the market. The rising demand for DNA oligos for DNA synthesis and adoption in drug development and research, is contributing to the growth of the segment. Further, increasing commercialization activities for new DNA fragments also drive segment growth.

• For instance, in July 2024, Ansa Biotechnologies, Inc., announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments.

Analysis by Application

By application, the market is categorized into next generation sequencing, CRISPR/functional genomics, gene variant libraries, and others.

The next-generation sequencing segment is expected to grow significantly during the forecast period. The increasing integration of NGS for drug discovery, personalized medicine, and genomic research augments the segment growth.

• For instance, in May 2024, Integrated DNA Technologies collaborated with the Bio-IT company with an aim to focus on integrating their next-generation sequencing (NGS) technologies with Molecular Health's variant annotation and reporting software to streamline genomics data workflows and accelerate cancer research.

Analysis by End User

Based on end user, the market is subdivided into pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and others.

The pharmaceutical & biotechnology companies segment held the largest share of the market. The increasing adoption of synthesized oligo products, such as DNA and RNA, by pharmaceutical and biotechnological companies to develop novel treatment options for different diseases pushes segment growth.

• For instance, in January 2024, Vertex Pharmaceuticals and CRISPR Therapeutics announced the U.S. health regulator's approval for gene therapy to treat a rare blood disorder requiring regular blood transfusions.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, has been analyzed across Asia Pacific, North America, Europe, the Middle East & Africa, and Latin America.

North America accounted for a dominant share of the global oligo pools market in 2025. The growing demand for personalized treatment options, new product launches, and the presence of manufacturing facilities are expected to boost the market's growth.

For instance, in March 2023, Oligo Factory opened a new oligo manufacturing facility in Holliston, Massachusetts. This facility increases Oligo Factory’s manufacturing capacity by 12x.

Europe holds a considerable market share. Increasing focus toward biopharmaceutical research and manufacturing facilities expansion for better patient outcomes is expected to drive the region's market growth.

• For instance, in April 2024, Asahi Kasei Bioprocess (AKB) and Axolabs partnered to build an oligonucleotide cGMP manufacturing facility in Berlin. The collaboration aimed to accelerate the development and commercialization of oligonucleotide-based therapies to improve patients' quality of life.

Moreover, the Asia Pacific market is expected to grow at a significant CAGR during the forecast period. The growing healthcare infrastructure and advancements in the oligo-based solution in molecular biology, and rising investments for launches of new manufacturing facilities are expected to drive the growth of the market.

Key Players Covered

The global oligo pools market is highly fragmented, with a large number of smaller providers.

The report includes the profiles of the following key players:

• Twist Bioscience (U.S.)
• Integrated DNA Technologies (IDT) (U.S.)
• GenScript (China)
• Agilent Technologies (U.S.)
• Eurofins (Luxembourg)
• Eurogentec (Belgium)
• Merck KGaA (Germany)
• LGC Biosearch Technologies (U.K.)

Key Industry Developments

• July 2025: Synoligo Biotechnologies Inc. announced the launch of its new e-commerce website for easy access to high-quality oligonucleotides for researchers.
• June 2024: GenScript launched GenScript FLASH Gene service, the ultra-fast sequence-to-plasmid (S2P) service to deliver gene constructs with unmatched speed, quality, and cost-efficiency.